BioTrove spits out RapidFire spinout Biocious Life Sciences

December 16, 2009 by MassDevice staff

Biocious Life Sciences, the spinout of BioTrove Inc.'s RapidFire drug screening business, is officially an independent entity.

Woburn, Mass.-based Biocious holds all of the RapidFire mass spectrometry intellectual property. The company also kept all of BioTrove's former RapidFire employees, including chairman and CEO Jeffrey Leathe and the rest of the company's management team.

The spinout is the result of Life Technologies Corp.'s acquisition of the rest of BioTrove. Carlsbad, Calif.-based Life Technologies bought the BioTrove brand and its OpenArray genotyping platform for an undisclosed amount last month. At the time BioTrove said it would spin out the RapidFire operation as Biocious after the merger closed.

The new company said its backers include Catalyst Health Ventures, Excel Venture Management, Fletcher-Spaght, CB Health Ventures, Vox Equity Partners, Echelon Ventures and BioFrontier Partners. The company's products and services are aimed at eliminating bottlenecks in drug discovery.

Leathe's management team includes COO Dr. Can "Jon" Özbal, and CFO Gary St. Pierre.

Permalink